Vermillion, Inc. (NASDAQ:VRML) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.97 and traded as high as $0.53. Vermillion shares last traded at $0.52, with a volume of 3,723 shares.
The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.91. The stock’s fifty day simple moving average is $0.59 and its 200-day simple moving average is $0.97.
Vermillion (NASDAQ:VRML) last issued its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. Vermillion had a negative net margin of 370.83% and a negative return on equity of 159.48%. The company had revenue of $1.14 million during the quarter.
A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Vermillion by 145.8% in the second quarter. Vanguard Group Inc. now owns 1,984,250 shares of the company’s stock valued at $1,766,000 after buying an additional 1,177,152 shares in the last quarter. Calamos Advisors LLC purchased a new position in Vermillion in the second quarter valued at about $712,000. Russell Investments Group Ltd. purchased a new position in Vermillion in the second quarter valued at about $278,000. Lincoln National Corp increased its stake in shares of Vermillion by 35.1% during the 2nd quarter. Lincoln National Corp now owns 174,916 shares of the company’s stock worth $156,000 after purchasing an additional 45,455 shares in the last quarter. Finally, CVI Holdings LLC purchased a new position in shares of Vermillion during the 2nd quarter worth approximately $71,000. 23.78% of the stock is owned by institutional investors.
Vermillion Company Profile (NASDAQ:VRML)
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.